Article

Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.

  • Views: 1669

  • Likes: 0

  • Citations: 7

Average (ratings)
No ratings
Your rating

Abstract

Natriuretic peptides play a crucial role in maintaining cardiovascular homeostasis. Among their properties are vasodilation, natriuresis, diuresis, and inhibition of cardiac remodeling. As heart failure progresses, however, natriuretic peptides fail to compensate. Knowledge of their processing and signaling pathways has guided the development of pharmacological therapies aimed at bolstering their effects. The drugs that have achieved the most clinical success have also stirred the most controversy. Nesiritide, the synthetic B-type natriuretic peptide, yielded significant symptomatic relief and improved haemodynamics but its use was plagued with questions surrounding its possibly harmful impact on renal function. More recently, compounds containing inhibitors of neprilysin, the enzyme responsible for degrading natriuretic peptides, have demonstrated morbidity and mortality benefit, but have also been linked to possible negative side effects. Clearly, potentiating the actions of natriuretic peptides for the benefit of patients is not as simple as just raising their serum concentration. This article reviews the current understanding of the compensatory actions of cardiac natriuretic peptides in heart failure and how this knowledge is revolutionizing heart failure therapy.

Keywords

ANP, BNP, heart failure, natriuretic peptides, neprilysin, nesiritide, LCZ696, omapatrilat,

Disclosure:NSL has no relevant disclosers to make. LBD has received consulting fees from Alere and diaDexus, and has received speaking fees from Critical Diagnostics and Roche Diagnostics.

Received:

Accepted:

DOI:https://doi.org/10.15420/cfr.2016:4:2

Correspondence Details:Lori B Daniels, Division of Cardiology, Sulpizio Cardiovascular Center, University of California, San Diego, Mail Code 7411, 9444 Medical Center Drive, La Jolla, CA 92037-7411, USA. E: lbdaniels@ucsd.edu

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Today, natriuretic peptides are ubiquitously utilized for the diagnosis, treatment, and prognostication of heart failure in the Emergency Department, as well as inpatient and outpatient settings alike.1–5 These endogenous hormones counteract some of the most detrimental effects of heart failure. Given their clinical and physiological importance, the fact that a manuscript describing the vasodilatory, diuretic, and natriuretic properties of atrial natriuretic peptide (ANP) – the first natriuretic peptide to be identified – was initially rejected from publication in 1980 today seems astonishing.6 The discovery propelled subsequent investigation that still continues over 30 years later. Much more detail is now known about these chemical messengers. This article reviews the current understanding of the compensatory actions of cardiac natriuretic peptides in heart failure and how this knowledge is revolutionizing heart failure therapy.

Background

Structurally related and made biologically active by a 17-amino-acid core ring and a cysteine bridge,7 the natriuretic peptides are a group of compounds that possess diverse actions in cardiovascular, renal, and endocrine homeostasis. The most recognized are ANP and B-type natriuretic peptide (BNP), which are released from both the atria and ventricles,8,9 and are the focus of this review. Other known natriuretic peptides include C-type natriuretic peptide (CNP), which is derived in the endothelium,10 Dendroaspis natriuretic peptidelike immunoreactivity (DNP-LI), which is present in the normal atrial myocardium and named for its structural similarity to a natriuretic peptide found in Dendroaspis angusticeps snake venom,11 and urodilatin, which is a component of human urine.12

Both ANP and BNP are secreted as pre-pro-polypeptides – that is, they are produced as inactive proteins attached to an N-terminal signal peptide, which is removed in the endoplasmic reticulum. After removal of the signal peptide, proANP – a 126-amino acid peptide – is stored in cardiac atria granulae.8 Upon cellular stimulation, such as myocardial stretch, vasoconstriction by endothelin, or increased levels of angiotensin II, a serine protease called corin cleaves proANP into the 28-amino-acid active ANP. In a normal healthy heart, ANP is not found in the ventricles. Heart failure is associated with a decrease in atrial ANP and increase in ventricular myocyte ANP.13

The mechanism of BNP activation is similar. Its pre-pro-polypeptide contains 134-amino acids.8 Removal of the N-terminal signal peptide generates proBNP1-108, which, after cellular stimulation, is cleaved by the serine proteases furin and corin into inactive N-terminal-proBNP (NT-proBNP) and active BNP1-32.14–16 Paralleling the expression of ANP in the progression of heart failure, the expression of BNP is solely derived from the atria in normal healthy conditions, increasing in the atria in early left ventricular dysfunction, and only later rising in the ventricle in overt volume overload.9

Active ANP and BNP bind to their receptor, natriuretic peptide receptor A (NPR-A), which is widely expressed in the body, including in the kidney, heart, lungs, brain, adrenal glands, adipose tissue, and vasculature. This binding activates guanylyl cyclase. The resulting increase in cyclic guanosine monophosphate (cGMP) mediates several protective mechanisms within the renal, vascular, and cardiac systems as discussed below. The active peptides are removed from circulation by natriuretic peptide receptor C (NPR-C) and degraded by neutral endopeptidase 24.11 (NEP), also known as neprilysin.8,17 Insulin-degrading enzyme (IDE) is also involved in natriuretic peptide cleavage.18Figure 1 shows a simplified portrait of ANP and BNP cellular processing.

Physiological Effects

The neurohumoral response to heart failure is complex and incompletely understood. It involves a multitude of peptides and mediators. One can consider a simplified model composed of two opposite yet complementary forces, though. On one hand are the sympathetic nervous system, renin–angiotensin–aldosterone system, and vasopressin, which work together to preserve cardiac output via fluid retention, augmented contractility, and increased heart rate. These effects are vasoconstricting, anti-natriuretic, anti-diuretic, and growth-promoting. On the other hand are the natriuretic peptides, which are vasodilating, natriuretic, diuretic, and anti-mitogenic, protecting against fibrosis and hypertrophy.19–25 BNP may inhibit the sympathetic nervous system directly as well.26

At first, the two sides seem to function in harmony. But chronically, the continuous fight to maintain cardiac output leads to volume overload. Natriuretic peptides eventually fail to compensate, and a vicious cycle of worsening heart failure perpetuates itself.

What causes the collapse of these compensatory measures? The breakdown is multifactorial. Studies suggest that in acute heart failure, the body reaches a maximum level of circulating natriuretic peptide that cannot be surpassed with greater elevations in atrial pressure.27,28 Even as higher pressures become longstanding, the body still cannot mount more natriuretic peptide, underscoring an impaired compensatory capacity during chronic volume overload.27 Research has also demonstrated reduced corin levels and predominantly altered, inactive forms of natriuretic peptide in patients with decompensated heart failure.29,30 High-molecular-weight forms of BNP, for example, have been isolated from patient samples, likely a combination of proBNP1-108 and its polymers.31–35 Further proteolyzed, degraded forms of BNP have also been quantified.36

Inability to produce and release active forms of natriuretic peptide is not the only hindrance to the body’s efforts to protect itself. In chronic severe heart failure, the end organs are also unable to respond fully to the hormone that is released into the bloodstream. Blunted natriuresis and vasodilatation have been shown in experimental heart failure.37–39 Explanations for the attenuated response to natriuretic peptides in chronic heart failure include NPR-A downregulation and desensitization to cGMP due to chronically high ANP and BNP levels. Tsutamoto et al. compared the plasma ANP and cGMP levels in patients with chronic mild to moderate heart failure with those in patients with chronic severe heart failure.40 Although plasma ANP and cGMP levels were positively correlated in the first group, no significant correlation was found in the latter group.40 Moreover, despite high concentrations of ANP in patients with chronic severe heart failure, cGMP concentrations plateaued.40

Basic Mechanism of ANP and BNP Cellular Processing

Article image
Download

Therapeutic Strategies

Given the beneficial effects of natriuretic peptides, four main strategies seem plausible for increasing their plasma concentrations in hopes of potentiating and prolonging their compensatory actions: 1) by activating corin and furin; 2) by administering recombinant natriuretic peptides; 3) by antagonizing NPR-C; or 4) by inhibiting NEP. Of these targets, recombinant natriuretic peptides and NEP inhibitors have been most actively developed and hold the most clinical promise.

Recombinant Natriuretic Peptides

Infusions of synthetic ANP (such as anaritide and carperitide) have been used for years in Japan to treat hospitalized patients with acute decompensated heart failure.41 Small s udies of synthetic ANP in chronic heart failure as well have demonstrated vasodilatory and diuretic benefits, in addition to enhanced renal blood flow and glomerular filtration rate.42,43 Synthetic BNP (nesiritide), however, has made bigger headlines in the US since it gained US Food and Drug Administration (FDA) approval in 2001.

Colucci et al. first studied the clinical use of nesiritide in hospitalized patients with acute decompensated heart failure in a two-part multi-center study: an efficacy trial and a comparative trial.44 The efficacy trial, which aimed to evaluate the drug’s short-term effects on haemodynamics, global clinical status (judged independently by both the patient and the investigator), and symptoms, included 127 patients with a pulmonary capillary wedge pressure (PCWP) of at least 18 mmHg and a cardiac index of no more than 2.7 l/min/m2. Using a double-blind placebo-controlled design, the subjects were randomised to a 6-hour infusion of either placebo or low- or high-dose nesiritide. The low-dose group received a 0.3 μg/kg bolus followed by an infusion at 0.015 μg/kg/min. The high-dose group received a 0.6 μg/kg bolus followed by 0.030 μg/kg/min.

Results demonstrated a dose-dependent and statistically significant decrease in PCWP and increase in cardiac index in the nesiritide groups (p<0.001). Patient-reported global clinical status improvement was noted in 60 % and 67 % of patients in the low- and high-dose nesiritide groups, respectively, compared with 14 % of patients receiving placebo (p<0.001 for both comparisons). Physician-reported global clinical status improvement was observed in 55 % and 77 % of patients in the low- and high-dose nesiritide groups, respectively, compared with 5 % of patients receiving placebo (p<0.001 for both comparisons). Similarly, patients on nesiritide reported statistically significant improvements in dyspnea and fatigue.

In the comparative trial, 305 patients were randomly assigned in a 1:1:1 ratio to ‘open label standard therapy’ (consisting of single vasoactive drug therapy, such as dobutamine, milrinone, nitroglycerin, or nitroprusside) or double-blind dosing of nesiritide (at the same dosing as the efficacy trial) for up to 7 days. Most patients in the study were treated for 1–2 days, and all groups witnessed improvement in global clinical status, dyspnea, and fatigue at 6 hours, 24 hours, and at the end of therapy. None of the results showed significant differences between nesiritide and standard therapy, though.

Dose-related hypotension was the main adverse effect in these trials. Although predominantly asymptomatic, symptomatic hypotension occurred in 4 % of the standard-therapy group in the comparative trial, compared with 11 % and 17 % of the low- and high-dose nesiritide groups, respectively (p=0.008). The investigators argued that in clinical practice, the incidence of hypotension would be minor because the initial nesiritide dose would be low and titrated to blood pressure. Overall, the study concluded that nesiritide could achieve rapid symptomatic relief and improved haemodynamics in hospitalized patients.44

Given questions over adverse blood pressure effects, a larger bolus dose but smaller infusion dose was used in the Vasodilatation in the Management of Acute Congestive Heart Failure (VMAC) trial.45 This multi-center prospective, randomised, double-blind trial sought to evaluate the efficacy and safety of intravenous nesiritide compared with intravenous nitroglycerin and placebo. The study involved 489 hospitalized patients with acute decompensated heart failure and New York Heart Association class IV symptoms. Nesiritide was given as a 2 μg/kg bolus followed by an infusion of 0.01 μg/kg/min for 3 hours. At 3 hours, reduction in PCWP from baseline was significantly greater in the nesiritide group (p<0.001 compared with placebo; p=0.03 compared with nitroglycerin). Although nesiritide provided significant symptomatic relief compared with the placebo, no significant difference was found compared with nitroglycerin. Rates of hypotension were similar between nesiritide and nitroglycerin, and again, most hypotensive episodes were mild.45

Skepticism over the drug continued when a meta-analysis of randomised clinical trials later raised concern that nesiritide significantly increased the risk of renal impairment, even at the lowest dose.46 In response to the enormous controversy, the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) was undertaken. The trial randomised 7,141 patients with acute, decompensated heart failure to receive standard therapy in addition to either placebo or nesiritide.47 ASCEND-HF confirmed that nesiritide had no effect on renal function. Investigators postulated that the meta-analysis results were at least in part due to inclusion of studies that did not compare nesiritide with a placebo but with drugs like dobutamine or nitroglycerin, which could have improved renal function. Still, the earlier concerns, coupled with studies highlighting lack of significant improvement in re-hospitalisation, mortality, or symptoms, led to a drastic decrease in the use of nesiritde.48,49

NEP Inhibition

After the rise and fall of synthetic BNP, investigators have focused more on NEP inhibition. Small studies with NEP inhibitors like candoxatril and sinorphan have shown that halving NEP activity effectively doubles the ANP level.50 NEP inhibition also circumvents the unwanted physiological effects of diuretic therapy like increased renin and aldosterone.51 Some studies reported clinical benefits, although the results were limited by very short-term therapy. One of them found an association with decreased PCWP, but only 12 male patients were included, with a treatment duration of 2 days.50 Another study demonstrated improved exercise duration over 12 weeks of therapy, although the result was not statistically significant.52 Despite these promising characteristics, NEP inhibitors did not result in a significant decrease in blood pressure;53 in fact, these drugs actually increased systolic pressure in healthy subjects.54 This initially unexpected effect was later attributed to the fact that angiotensin II and endothelin I are NEP substrates as well.55,56 As such, the haemodynamic result of NEP inhibitors is not simply a vasodilatory response to increased natriuretic peptide levels but dependent on the net balance with its vasopressor effects as well.

The complex interaction between these drugs and the renin– angiotensin–aldosterone system was demonstrated in a study in which two groups of healthy subjects displayed opposite haemodynamic responses to NEP inhibition.57 Subjects were pretreated with either low or high doses of candoxatril, then administered stepwise infusions of angiotensin II. Angiotensin II concentrations were augmented in both groups, particularly with higher doses of candoxatril. Whereas the lower dose of candoxatril was associated with about a 10 mmHg increase in systolic and diastolic blood pressures, the higher dose was not.57 Possible explanations were that the modest negative sodium balance that resulted in the high-dose group reduced the pressor response to angiotensin II, and that higher doses of candoxatril enhanced ANP enough to offset the angiotensin II pressor action as well. These results suggested that in high renin states, NEP inhibitors could exacerbate hypertension; but in low renin states, these drugs could potentiate vasodilation.

Combination Therapy

To combat the blood pressure effect, ‘vasopeptidase inhibitors’ like omapatrilat – containing a combination of an angiotensin-convertingenzyme (ACE) inhibitor and a NEP inhibitor – were developed. But, despite its theoretical promise, omapatrilat had disappointing results. In the Omapatrilat versus Enalapril Randomised Trial of Utility in Reducing Events (OVERTURE), the study drug proved non-inferior to enalapril in decreasing mortality and rates of heart failure hospitalisation requiring intravenous therapy among 5,770 patients, but more patients treated with omapatrilat experienced angioedema (0.8 % versus 0.5 % with enalapril)58, likely because bradykinin is also a substrate of NEP.59 More specifically, bradykinin degradation is dependent on ACE, aminopeptidase P, dipetidyl peptidase IV, and NEP.60 Many ACE inhibitors are known to inhibit aminopeptidase P as well.61 In the face of a NEP inhibitor/ACE inhibitor combination drug, bradykinin clearance relies heavily on dipetidyl peptidase IV, whereas an ACE inhibitor alone produces less blockade of these metabolic pathways (as does a combination NEP inhibitor/angiotensin receptor blocker).

The Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) study employed lower doses of omapatrilat in 25,302 patients with hypertension (not heart failure) and again confirmed significantly more cases of angioedema (2.2 versus 0.7 %; p<0.005).62 Given the lack of benefit in heart failure compared with standard therapy, and significant safety concerns, the drug never gained FDA approval.

Summary of Neutral Endopeptidase 24.11 Inhibition Studies

Article image
Download

Researchers returned to the drawing boards, formulating a plan to combat the unwanted angioedema of omapatrilat while still considering the lessons learned from prior manipulations of the natriuretic peptide system. The result was LCZ696: a combination of the angiotensin II receptor blocker valsartan and NEP inhibitor sacubitril. So far, the drug has achieved very promising results.

The Prospective comparison of Angiotensin Receptor neprilysin inhibitors with Angiotensin converting enzyme inhibitors to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGMHF) study was stopped early due to the unequivocal benefit found with LCZ696 after a median follow-up of 27 months.59,63 This double-blind study of 8,442 patients with symptomatic chronic systolic heart failure with reduced ejection fraction of ≤40 % (the protocol was later adjusted to ≤35 %, and the mean was 30 %) compared twice daily dosing of LCZ696 with enalapril, showing reduction in the composite endpoint of death from cardiovascular causes or hospitalisation for heart failure (hazard ratio 0.80; 95 % CI [0.73–0.87]; p<0.001), as well as a reduction in all-cause mortality (hazard ratio 0.84; 95 % CI [0.76–0.93]; p<0.001).59 Symptomatic hypotension was more common with LCZ696 than with enalapril but did not lead to increased discontinuation of therapy. Two welcomed results with respect to the previous nesiritide and omapatrilat controversies were: 1) increases in serum creatinine and related discontinuation of therapy were more common with enalapril; and 2) as expected, LCZ696 was not associated with an increased risk of angioedema59 (since this drug leaves both ACE and aminopeptidase P to clear bradykinin). Criticisms of PARADIGM-HF include that although LCZ696 employs the maximum dose of valsartan, the study compared the drug with half the maximum dose of enalapril.

With these promising findings, investigators sought to determine whether substantial morbidity and mortality benefit extended to heart failure patients with preserved ejection fraction. The first step was the Prospective Comparison of angiotensin receptor-neprilysin inhibitor with angiotensin receptor blocker on Management of Heart Failure with Preserved Ejection Fraction (PARAMOUNT) study, a phase-2, randomised, double-blind trial to examine the efficacy and safety of LCZ696 in this population. Patients were randomised to 200 mg of LCZ696 twice daily or 160 mg valsartan twice daily for 36 weeks. Chosen for its association with adverse outcomes in heart failure patients, the primary endpoint examined change in NT-proBNP. Results demonstrated a greater reduction in NT-proBNP in the LCZ696 group (p=0.01), and similar rates of hypotension and renal impairment compared with valsartan alone.64 The Prospective comparison of Angiotensin Receptorneprilysin inhibitor with Angiotensin receptor blocker Global Outcomes in heart failure with preserved ejection fraction (PARAGON) trial is a phase-3 study aiming to build on this data and support the morbidity and mortality benefit seen in PARADIGM-HF for heart failure patients with preserved ejection fraction.65

The NEP inhibition studies are summarized in Table 1.

Effect of NEP Inhibition on Clinical use of Natriuretic Peptide Levels

Current American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) heart failure practice guidelines give measurement of BNP or NT-proBNP a Class I recommendation for both diagnosing and establishing prognosis in heart failure, and a Class II recommendation for guiding therapy.66 With the FDA approval of LCZ696 (sacubitril/valsartan), important questions arise as to how this drug and other neprilysin inhibitors will affect the clinical interpretation of natriuretic peptide levels for each of these indications. In the PARADIGMHF trial, LCZ696 was associated with a significant increase in BNP and urinary cGMP levels at 4 weeks and 8 months compared with enalapril (p<0.0001).67 In contrast, NT-proBNP and troponin T levels were lower in patients receiving LCZ696 than in those receiving enalapril (p<0.0001). A similar effect on NT-proBNP levels was seen in PARAMOUNT.64

The PARADIGM-HF authors suggest that among patients receiving LCZ696, increased levels of BNP may be related to the mechanism of the drug (since inhibiting neprilysin augments BNP concentration), whereas decreased levels of NT-proBNP (which is not a substrate for neprilysin) may be indicative of the cardiac effects of the drug in reducing wall stress and myocyte injury.67 If this hypothesis is correct, NT-proBNP may be a more appropriate marker choice for monitoring heart failure patients on neprilysin inhibitors, though this theory has not yet been proven. If true, ANP, CNP, and their respective N-terminal peptides could also be considered as monitoring biomarkers, as neprilysin has higher affinity for these peptides;68 assays for NT-proBNP and BNP, however, are currently in wider clinical use.

An alternate explanation is possible. Analyses of blood samples from heart failure patients reveal that proBNP and NT-proBNP undergo post-translational modifications including glycosylation at several sites.69 Most assays for NT-proBNP rely on antibodies directed against epitopes that can undergo glycosylation.69,70 Glycosylation, however, interferes with antibody binding.69 Neprilysin inhibitors may cause assays to underrepresent the actual concentration of NT-proBNP by increasing glycosylation of NT-proBNP.71 How these neprilysin inhibitor-induced changes in natriuretic peptide measurements will affect the accuracy and implications of assay results has not been studied yet. At the very least, cutpoints will likely need to be recalibrated for use in patients on these drugs, particularly if BNP is being measured. Regardless, more studies are needed to help guide the optimal use of BNP and/or NT-proBNP measurements in patients taking neprilysin inhibitors.

Conclusion

Great steps have been made in harnessesing the understanding of natriuretic peptide processing and signaling for heart failure therapy. The resulting drugs have aimed to reinforce the ability of natriuretic peptides to compensate for the ill-effects of the sympathetic nervous system and renin–angiotensin–aldosterone system in chronic heart failure. Despite the latest success in NEP inhibitor combination therapies, controversy surrounding these drugs has not waned, including a theoretical concern of reduced amyloid beta degradation and consequent increased longterm risk of Alzheimer’s dementia.72 Clinicians still must weigh the intended benefits with the potential unwanted side effects of these therapies. The long-term efficacy and risks of these drugs are still unknown, as are the optimal ways to utilise natriuretic peptide assays in patients on these drugs, and their economic impacts, though much of these uncertainties will be sorted out with time. So far, this story is one of success, but its ending remains unwritten as we await further data to guide our targeted titration of agents in the natriuretic peptide system to the benefit of our patients.

References

  1. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062–76. 
    Crossref | PubMed
  2. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106:416– 22.
    Crossref | PubMed
  3. Daniels LB. Natriuretic peptides and assessment of cardiovascular disease risk in asymptomatic persons. Curr Cardiovasc Risk Rep 2010;4:120–7.
    Crossref | PubMed
  4. Daniels LB, Clopton P, Jiang K, et al. Prognosis of stage A or B heart failure patients with elevated B-type natriuretic peptide levels. J Card Fail 2010;16:93–8. 
    Crossref | PubMed
  5. Betti I, Castelli G, Barchielli A, et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. J Card Fail 2009;15:377–84.
    Crossref | PubMed
  6. de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Reprinted from Life Sci 1981;28:89–94. J Am Soc Nephrol 2001;12:403–9; discussion 403–8, 408–9. 
    PubMed
  7. Misono KS, Fukumi H, Grammer RT, et al. Rat atrial natriuretic factor: complete amino acid sequence and disulfide linkage essential for biological activity. Biochem Biophys Res Commun 1984;119:524–9. 
    Crossref | PubMed
  8. Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001;51:442–9.
    Crossref | PubMed
  9. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684–9.
    PubMed
  10. Izumiya Y, Araki S, Usuku H, et al. Chronic C-type natriuretic peptide infusion attenuates angiotensin II-induced myocardial superoxide production and cardiac remodeling. Int J Vasc Med 2012;2012:246058. 
    Crossref | PubMed
  11. Schirger JA, Heublein DM, Chen HH, et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999;74:126–30.
    Crossref | PubMed
  12. Koh CY, Kini RM. From snake venom toxins to therapeutics-- cardiovascular examples. Toxicon 2012;59:497–506.
    Crossref | PubMed
  13. Edwards BS, Ackermann DM, Lee ME, et al. Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest 1988;81:82–6.
    Crossref | PubMed
  14. Semenov AG, Tamm NN, Seferian KR, et al. Processing of pro-B-type natriuretic peptide: furin and corin as candidate convertases. Clin Chem 2010;56:1166–76.
    Crossref | PubMed
  15. Hayek S, Nemer M. Cardiac natriuretic peptides: from basic discovery to clinical practice. Cardiovasc Ther 2011;29:362–76. 
    Crossref | PubMed
  16. Ichiki T, Huntley BK, Burnett JC, Jr. BNP molecular forms and processing by the cardiac serine protease corin. Adv Clin Chem 2013;61:1–31.
    Crossref | PubMed
  17. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004;109:1680–5.
    Crossref | PubMed
  18. Ralat LA, Guo Q, Ren M, et al. Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response. J Biol Chem 2011;286:4670–9. doi:  
    Crossref | PubMed
  19. Holmes SJ, Espiner EA, Richards AM, et al. Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. J Clin Endocrinol Metab 1993;76:91–6.
    Crossref | PubMed
  20. Holtwick R, van Eickels M, Skryabin BV, et al. Pressureindependent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003;111:1399–407. 
    Crossref | PubMed
  21. Kuhn M, Holtwick R, Baba HA, et al. Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice. Heart 2002;87:368–74.
    Crossref | PubMed
  22. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990;86:1690–7.
    Crossref | PubMed
  23. Knowles JW, Esposito G, Mao L, et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J Clin Invest 2001;107:975–84.
    Crossref | PubMed
  24. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growthpromoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101:812–8. 
    Crossref | PubMed
  25. Horio T, Nishikimi T, Yoshihara F, et al. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension 2000;35:19–24.
    Crossref | PubMed
  26. Brunner-La Rocca HP, Kaye DM, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221–7.
    Crossref | PubMed
  27. Redfield MM, Edwards BS, McGoon MD, et al. Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. Circulation 1989;80:651-7.
    Crossref | PubMed
  28. Volpe M, Tritto C, De Luca N, et al. Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure. J Clin Invest 1991;88:1481–9. 
    Crossref | PubMed
  29. Xu-Cai YO, Wu Q. Molecular forms of natriuretic peptides in heart failure and their implications. Heart 2010;96:419–24.
    Crossref | PubMed
  30. Ibebuogu UN, Gladysheva IP, Houng AK, et al. Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide. Circ Heart Fail 2011;4:114–20. 
    Crossref | PubMed
  31. Hawkridge AM, Heublein DM, Bergen HR, 3rd, et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 2005;102:17442– 7.
    Crossref | PubMed
  32. Seferian KR, Tamm NN, Semenov AG, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866–73. 
    Crossref | PubMed
  33. Seidler T, Pemberton C, Yandle T, et al. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun 1999;255:495–501.
    Crossref | PubMed
  34. Shimizu H, Masuta K, Aono K, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002;316:129–35.
    Crossref | PubMed
  35. Tateyama H, Hino J, Minamino N, et al. Concentrations and molecular forms of human brain natriuretic peptide in plasma. Biochem Biophys Res Commun 1992;185:760–7. 
    Crossref | PubMed
  36. Niederkofler EE, Kiernan UA, O’Rear J, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008;1:258–64. 
    Crossref | PubMed
  37. Scriven TA, Burnett JC, Jr. Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation 1985;72:892-7. 
    Crossref | PubMed
  38. Margulies KB, Heublein DM, Perrella MA, et al. ANFmediated renal cGMP generation in congestive heart failure. Am J Physiol 1991;260:F562–8. 
    PubMed
  39. Edvinsson ML, Uddman E, Edvinsson L, et al. Brain natriuretic peptide is a potent vasodilator in aged human microcirculation and shows a blunted response in heart failure patients. J Geriatr Cardiol 2014;11:50–6.
    Crossref | PubMed
  40. Tsutamoto T, Kanamori T, Wada A, et al. Limitations of compensation by endogenous atrial natriuretic peptide in heart failure. Jpn Circ J 1992;56:489–93. 
    Crossref | PubMed
  41. Dohi K, Ito M. Novel diuretic strategies for the treatment of heart failure in Japan. Circ J 2014;78:1816–23. 
    Crossref | PubMed
  42. Fifer MA, Molina CR, Quiroz AC, et al. Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. Am J Cardiol 1990;65:211–6. 
    Crossref | PubMed
  43. Kitashiro S, Sugiura T, Takayama Y, et al. Long-term administration of atrial natriuretic peptide in patients with acute heart failure. J Cardiovasc Pharmacol 1999;33:948–52. 
    Crossref | PubMed
  44. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246–53. 
    Crossref | PubMed
  45. Publication Committee for the VI. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomised controlled trial. JAMA 2002;287:1531–40. 
    Crossref | PubMed
  46. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487–91. 
    Crossref | PubMed
  47. van Deursen VM, Hernandez AF, Stebbins A, et al. Nesiritide, renal function, and associated outcomes during hospitalisation for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). Circulation 2014;130:958–65.
    Crossref | PubMed
  48. Hauptman PJ, Schnitzler MA, Swindle J, et al. Use of nesiritide before and after publications suggesting drugrelated risks in patients with acute decompensated heart failure. JAMA 2006;296:1877–84. 
    Crossref | PubMed
  49. O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32–43.
    Crossref | PubMed
  50. Kahn JC, Patey M, Dubois-Rande JL, et al. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 1990;335:118–9.
    Crossref | PubMed
  51. Westheim AS, Bostrom P, Christensen CC, et al. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol 1999;34:1794–801.
    Crossref | PubMed
  52. Northridge DB, Currie PF, Newby DE, et al. Placebocontrolled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail 1999;1:67–72.
    Crossref | PubMed
  53. Bevan EG, Connell JM, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607–13.
    Crossref | PubMed
  54. Ando S, Rahman MA, Butler GC, et al. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26:1160–6.
    Crossref | PubMed
  55. Pankow K, Wang Y, Gembardt F, et al. Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide. Circ Res 2007;101:875–82. 
    Crossref | PubMed
  56. Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407–16.
    Crossref | PubMed
  57. Richards AM, Wittert GA, Espiner EA, et al. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992;71:1501–7.
    Crossref | PubMed
  58. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomised Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920–6.
    Crossref | PubMed
  59. McMurray JJ, Packer M, Desai AS, et al. Angiotensinneprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. 
    Crossref | PubMed
  60. Craig TJ, Bernstein JA, Farkas H, et al. Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting. Int Arch Allergy Immunol 2014;165:119–27. 
    Crossref | PubMed
  61. Hooper NM, Hryszko J, Oppong SY, et al. Inhibition by converting enzyme inhibitors of pig kidney aminopeptidase P. Hypertension 1992;19:281–5.
    Crossref | PubMed
  62. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17:103–11.
    Crossref | PubMed
  63. McMurray JJ, Packer M, Desai AS, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15:1062–73. 
    Crossref | PubMed
  64. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012;380:1387–95.
    Crossref | PubMed
  65. Novartis Pharmaceuticals. Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2003– [cited 2015 Dec 05]. Available from: https://www.clinicaltrials.gov/ct2/ show/NCT01920711 NLM Identifier: NCT01920711.
  66. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239. 
    Crossref | PubMed
  67. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015;131:54–61.
    Crossref | PubMed
  68. Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discovery Today: Therapeutic Strategies 2012;9:e131–9. 
    Crossref
  69. Mair J. Clinical significance of pro-B-type natriuretic peptide glycosylation and processing. Clin Chem 2009;55:394–7. 
    Crossref | PubMed
  70. Seferian KR, Tamm NN, Semenov AG, et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008;54:866–73. 
    Crossref | PubMed
  71. Jaffe AS, Apple FS, Mebazaa A, et al. Unraveling N-terminal pro-B-type natriuretic peptide: another piece to a very complex puzzle in heart failure patients. Clin Chem 2015;61:1016–8. 
    Crossref | PubMed
  72. Li Y, Wang J, Zhang S, et al. Neprilysin gene transfer: A promising therapeutic approach for Alzheimer’s disease. J Neurosci Res 2015;93:1325–9. 
    Crossref | PubMed
Previous Volume Article Next Volume Article